IBUPROFEN API
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 43%
While the indices might be witnessing correction on intra intra-basis, the broader markets are still very much under the control of the bulls. There is greater likelihood of bullish sentiment continuing, so be bullish but more than anything else in the long term what matters for a stock is earnings and valuation. So be selective, avoid impulsive investing, and keep reviewing one’s portfolio and stay away from penny stocks especially. It is very likely that some of the penny stocks will fly and be distributed amongst retail investors. We look at stocks which have witnessed a continuous rise in their score in the last one month. These selected stocks depict a strong upward trajectory in their overall average score which is based on five key pillars i.e. earnings, fundamentals, relative valuation, risk and price momentum. This implies that there has been a significant improvement in their market outlook in the given time frame.
US FDA inspects Vishakhapatnam facility of Solara Active Pharma
The US Food and Drug Administration (FDA) completes inspection of Solara Active Pharma Sciences' API manufacturing facility in Visakhapatnam, Andhra Pradesh, with no observations. Solara confirms compliance with FDA standards. The facility, dedicated to Ibuprofen API production, marks Solara's second successful FDA inspection. The company aims for global market expansion with FDA-approved facilities.
On a path to recovery: 4 small pharma stocks with an upside potential of up to 27%
As the markets get jittery, select pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are small and mid sized Indian pharma companies which are not hit by pricing pressure of the US generic market and other issues which large pharma companies are facing. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list.
Weekly Top Picks: 4 stocks with consistent score improvement & upside potential of up to 68%
Is the up move of Nifty on friday, a dead cat bounce or it is the start of a sustainable rally. Rather than worrying about it is better to focus on stocks. The selected stocks depict a strong upward trajectory in their overall average score which is based on five key pillars i.e. earnings, fundamentals, relative valuation, risk and price momentum. This implies that there has been a significant improvement in their market outlook in the given time frame.
Covid uncertainty in China getting expressed as market volatility: Steve Sosnick
“We are starting to see a lot of production move to other places and one of the stories for Indian investing over the coming years will be how India can benefit from this move away from China. But in the short term, this is problematic because it raises the problems that a lot of the world’s raw ingredients or a lot of the early stage and even later stage manufacturing is coming from one place.”
IOL Chemicals gets EDQM certification for API supply to Europe
The European Directorate for the Quality of Medicines & HealthCare (EDQM) is a mandatory certification for distribution of any API/ pharma products in Europe. Pantoprazole Sodium Sesquihydrate, an active pharmaceutical ingredient (API), is proton pump inhibitor used in drugs to suppress the gastric acid secretion. "The company started production of Pantoprazole Sodium Sesquihydrate in Q3 FY 2020 at its Punjab-based facility.
- Go To Page 1
IOL to diversify its API and specialty chemicals portfolios to boost sales
The Ludhiana-based company generates about 30% of its ₹2,216 crore revenues from the commodity API ibuprofen, where it is vertically integrated manufacturing the key starting material Isobutylbenzene needed for making the drug. Ibuprofen, an age-old drug, is used in the treatment of pain.
India hopes 'pharma city' in Hyderabad will break China’s grip on the industry
At the heart of the endeavor is India’s race to wrest control from China, which supplies almost 70% of the active pharmaceutical ingredients -- or the bread-and-butter chemicals -- that go into the medicines produced by the Indian pharmaceutical industry
Rahul Sharma is betting on Lemon Tree, LGB and IOL Chemicals. Here’s why
“Hotel stocks have rallied well but Lemon Tree has not participated though it has really good potential to go beyond these levels.”
Costs of raw material for drugs rise by up to 140%
API prices of certain drugs like fever and pain relief drug paracetamol and life-saving antibiotic Meropenem (also used for Covid), and anti-diabetic metformin, have more than doubled to as high as 139%, 127% and 124% respectively, putting the spotlight back on India’s near total-dependence on the Dragon.
Granules India earmarks capex of Rs 1,000 crore till FY24
The Hyderabad-based firm plans to invest in a new manufacturing facility and on expanding production capacities at existing plants.
Sell on rise if Nifty closes above 14,900: Rahul Sharma
Similarly for Bank Nifty, 34,000 will act as a strong hurdle till we get a closing above 34,000.
As India battled Covid-19, FIIs ran to grab opportunity in diagnostics
Healthcare has been the top performing sector in 2020, as defensives became fashionable. And the FII bets seems to have paid off well, as these stocks logged decent gains all through July.
Stock Ideas: Anand Rathi has a buy call on Granules India, target price Rs 227
. The brokerage expects ~25 per cent/~23 per cent revenue/PAT CAGRs over FY20-22.
Covid-19 outbreak: Pharma companies airlift inputs to deal with supply disruptions
Considering the criticality in respect of Active Pharmaceutical Ingredients (APIs) and Key Starting Material (KSMs), the companies have started to airlift material from China too. Mankind has also airlifted material recently for making antibiotics and vitamins from China, Juneja confirmed.
After 1,800% jump in 10 years, this pharma stock is in no mood to halt
The company is one of the active ingredients and drug formulations makers.
Coronavirus: How it impacts your money
As trade and commerce get disrupted, Indian companies are likely to feel the heat as well.
Ficci: Some drugs may not last beyond Feb because of virus crisis
India depends on China for around 70% of its bulk drugs and drug intermediates, according to industry estimates. This is the first-of-its-kind study based on feedback from the industry.
Blackstone, KKR, Bain among PE cos in talks to buy Granules India
The investor relations team at Granules India denied the promoters are seeking to sell their stake.
Buy Granules India, target Rs 127: Geojit Financial Services
The brokerage has set a one-year horizon for the stock to hit the target price.
Aurobindo in last lap to buy Mallinckrodt’s US generics business
Mallinckrodt has the world’s most diverse line of bulk medicinal controlled substances including fentanyl, methadone, hydrocodone, hydromorphone, oxycodone, morphine and codeine-based drugs.
Strides Shasun gets USFDA nod for generic Ibuprofen capsules
The generic Ibuprofen capsules, 200 mg, is meant for relieving pain and will be manufactured at the company's oral dosage facility in Bangalore.
26% dip in drug ingredient import from China
In 2017, India imported 354 Active Pharmaceutical Ingredients (APIs) from China, a 26% dip compared to 447 in 2015.
Markets on high: 9 less-known stocks to buy now
ET Wealth identifies nine lesser-known stocks that hold promise and can generate high returns in 2018 even as markets rise and valuations zoom.
Granules India's net profit up 26 pc to Rs 41 cr in Q2
The company's revenue increased by 3 per cent at Rs 364 crore as compared to Rs 353 crore in the corresponding period.
See considerable upside in Granules India; bullish on HSIL too: Vikas Sethi, Sethi Finmart Pvt Ltd
"Granules India is in the limelight and that has to do with the approval from US FDA "
India dependent on China for 12 drugs on National List of Essential Medicines: Government
India is largely dependent on China for imports of drug ingredients of 12 essential drugs which are in National List of Essential Medicines 2011.
Specialty chemicals stocks including Arti Industries, Camlin Fine and Deloitte's Kandaswamy rise up to 60%
Innovations, high margin, global opportunities help Specialty chemicals cos offer high returns against 3% gain by Sensex in past 1 year.
We can solve the Chinese pharma puzzle: C Krishna Prasad, MD, Granules Pharma
In a couple of years from now, China will be the third-largest pharmaceutical market in the world making medicines worth $40 billion.
Load More
